Cytochrome P450 and liver diseases

Area of Science:

• Pharmacology
• Hepatology
• Biochemistry

Background:

• Cytochrome P-450 (CYPs) enzymes are critical for metabolizing drugs, chemicals, and endogenous substrates.
• Hepatic CYPs play a significant role in the pathogenesis of various liver diseases, including drug-induced hepatotoxicity and autoimmune hepatitis.
• CYP-mediated activation of drugs can lead to toxic metabolites, causing hepatotoxicity, and in some cases, immune-mediated liver injury through anti-CYP antibodies.

Purpose of the Study:

• To review the multifaceted roles of Cytochrome P-450 enzymes in liver disease pathogenesis.
• To explore the involvement of specific CYP isoforms, such as CYP2E1, in conditions like alcoholic and non-alcoholic steatohepatitis.
• To discuss the impact of liver disease on drug metabolism mediated by CYPs and the potential of CYP activity as a biomarker for hepatic functional reserve.

Main Methods:

• Literature review and synthesis of existing research on Cytochrome P-450 enzymes and liver diseases.
• Analysis of studies investigating CYP-mediated drug toxicity and immune responses.
• Examination of research on the role of CYP2E1 in steatohepatitis and hepatocellular carcinoma.
• Evaluation of data on altered CYP expression and activity in various liver disease etiologies.

Main Results:

• CYP-mediated activation of drugs can cause hepatotoxicity, with examples like acetaminophen and halothane.
• Anti-CYP antibodies are implicated in immune-mediated hepatotoxicity and are found in patients with autoimmune hepatitis.
• CYP2E1 is strongly implicated in alcoholic liver disease and non-alcoholic steatohepatitis, associated with lipid peroxidation and oxidative stress.
• Drug metabolism is impaired in liver disease, with CYP1A, 2C19, and 3A being particularly vulnerable, while CYP2D6, 2C9, and 2E1 are less affected.
• CYP isoenzyme alterations vary by liver disease etiology, and a relationship exists between CYP activity and cirrhosis severity, though its utility for assessing hepatic reserve is uncertain.

Conclusions:

• Cytochrome P-450 enzymes are key players in both drug metabolism and the development of liver pathologies.
• Specific CYP isoforms like CYP2E1 are significantly involved in the pathogenesis of metabolic and alcohol-related liver diseases.
• Liver disease profoundly affects CYP-mediated drug metabolism, with implications for therapeutic strategies and the uncertain potential of CYP activity measurement for assessing liver function.